Lung Homogenate Preparation
Lung Homogenate Preparation - Related Videos
08:01
Preparation of Homogeneous MALDI Samples for Quantitative Applications
0 Views •
Cited by 8 •
2016
A protocol for reducing spatial heterogeneities of ion signals in MALDI mass spectrometry by regulating substrate temperature during sample drying processes is demonstrated.
05:55
Whole Lung Agarose Inflation: A Method of Preparing Lungs for Ex vivo Live Imaging
0 Views •
2023
This video describes a method of preparing lungs for ex vivo live imaging to study interactions between cancer cells and stromal cells, using agarose for inflation. In the sample protocol, agarose inflation procedure is described before observing live cellular interactions.
01:23
Test for Homogeneity
0 Views •
2023
The goodness–of–fit test can be used to decide whether a population fits a given distribution, but it will not suffice to decide whether two populations follow the same unknown distribution. A different test, called the test for homogeneity, can be used to conclude whether two populations have the same distribution. To calculate the test statistic for a test for homogeneity, follow the same procedure as with the test of independence. The hypotheses for the test for homogeneity can be stated as...
04:16
ECM Suspension Preparation: A Technique to Obtain Homogenous Suspension from Tissue-derived Extracellular Matrix
0 Views •
2023
This video describes the preparation of a homogenized and digested extracellular matrix suspension from decellularized and lyophilized tissues. This technique helps in fabricating ECM-derived porous foams and microcarriers for use as substrates in advanced 3D cell culture models.
04:26
Agarose-Based Preparation of Human Precision-Cut Lung Slices
0 Views •
2025
In this video, we describe a procedure to inflate isolated human lungs with agarose and prepare human precision-cut lung slices. The prepared ex vivo lung slices can be used for further immunologic experiments.
FAQs
Keeping the tissue in a chilled buffer during mechanical disruption helps maintain a consistent preparation while limiting loss or alteration of components that researchers intend to measure. The disruption step must be sufficient to release material from the lung, but standardized handling is equally important because differences in processing can affect the comparability of analyte measurements across experimental groups.
Filtration and centrifugation serve different separation roles within the workflow. Filtration can remove large debris from the suspension, whereas centrifugation can remove debris or divide the homogenate into fractions. The selected treatment therefore determines which portion of the lung sample proceeds to analysis, making separation important when interpreting cellular, soluble, nucleic-acid, or infectious measurements.
Standardization makes differences in pathogen burden, cytokines, immune-cell markers, or gene expression more likely to reflect biological differences rather than inconsistent tissue handling. Using comparable disruption, buffer conditions, and post-processing choices also supports interpretation of infection severity and treatment responses, especially when multiple experimental groups are analyzed.
A single prepared sample can support several measurement types. Cells can support immune-cell marker analysis, soluble proteins can be examined through cytokine measurements, nucleic acids enable gene-expression analysis, and infectious components support pathogen-burden assessment. Because these contents coexist in the preparation, researchers can examine pulmonary immunity and infection-related changes from a common tissue source.
Researchers begin with lung tissue, mechanically disrupt it in chilled buffer, and then apply optional filtration or centrifugation to remove large debris or obtain separated fractions. The resulting material is retained for the planned measurement, such as cytokines, pathogen burden, immune-cell markers, or gene expression. Consistent execution across samples is essential for comparison.
Researchers use this approach when they need tissue-level information from pulmonary infection or immune responses rather than a measurement limited to an isolated component. It can support assessment of pathogen burden, inflammatory cytokines, immune-cell markers, and gene expression, allowing studies to relate tissue findings to infection severity or evaluate responses to treatment.
Results should be linked to the fraction and analyte being examined. A pathogen-burden measurement addresses infectious material, cytokine values reflect soluble inflammatory components, immune-cell markers provide information about cellular features, and gene-expression data describe nucleic-acid-associated expression patterns. Comparing these outputs across standardized samples can reveal coordinated changes in pulmonary immunity, infection severity, or treatment response.